Loading
A phase 1/2 trial of WSD0922-FU in non-small-cell lung cancer, run by Wayshine Biopharm, Inc., now recruiting.
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06631989 by Wayshine Biopharm, Inc., with 100 participants planned, started 2024-09-04 and due to reach its primary completion in 2027-06-30. Interventions recorded: WSD0922-FU.
Shares Wayshine Biopharm, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.